SABCS 2016

Anthracycline in Early Breast Cancer: Regimens Offer Similar Outcomes

Anthracycline in Early Breast Cancer: Regimens Offer Similar Outcomes

By

Three cycles of epirubicin plus cyclophosphamide (EC) followed by docetaxel (EC-D) offered no survival benefits.

Prognostic Signatures for Foregoing Extended Endocrine Therapy in Breast Cancer

Prognostic Signatures for Foregoing Extended Endocrine Therapy in Breast Cancer

By

Used alongside clinical variables, molecular prognostic signatures can identify postmenopausal women with ER+, HER2-negative breast cancer.

Breast Cancer: Taselisib Shows Preclinical Advantage Over Other PI3K Inhibitors

Breast Cancer: Taselisib Shows Preclinical Advantage Over Other PI3K Inhibitors

By

Findings from a preclinical study of PI3K inhibitor taselisib's mechanism of action in mutant cell line and breast cancer xenograft models surprised researchers.

ERα-Targeting PROTACs Show Preclinical Promise Against ER+ Breast Cancer

ERα-Targeting PROTACs Show Preclinical Promise Against ER+ Breast Cancer

By

An orally-available formulation of proteolysis-targeting chimera (PROTAC) successfully degraded and reduced levels of estrogen-receptor alpha (ERα) protein.

BRCA Mutations Associated With Carboplatin Outcomes in Triple-negative Breast Cancer

BRCA Mutations Associated With Carboplatin Outcomes in Triple-negative Breast Cancer

By

BRCA1 and BRCA2 mutation status predicts PFS in carboplatin-treated women with recurrent or metastatic triple-negative breast cancer (TNBC).

Dietary Fat Intervention Fails To Reduce Breast Cancer-related Deaths

Dietary Fat Intervention Fails To Reduce Breast Cancer-related Deaths

By

Dietary fat interventions in healthy postmenopausal women do not appear to lower the risk of breast cancer death.

Duloxetine Improves Aromatase Inhibitor-related Joint Pain

Duloxetine Improves Aromatase Inhibitor-related Joint Pain

By

Duloxetine treatment is superior to placebo for managing aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS).

Exercise and Gene Expression in Breast Cancer

Exercise and Gene Expression in Breast Cancer

By

Physical exercise might modulate the upregulation of immune and inflammatory-pathways involved in breast cancer.

DCIS Risk Biomarker Helps Identify Patients for Radiotherapy

DCIS Risk Biomarker Helps Identify Patients for Radiotherapy

By

A biological risk profile can identify patients with ductal carcinoma in situ (DCIS) who are at high risk of recurrence and might benefit from radiotherapy.

Aromatase Inhibitor Therapy and Cardiovascular Disease Risk

Aromatase Inhibitor Therapy and Cardiovascular Disease Risk

By

Aromatase inhibitor (AI) therapy is associated with endothelial dysfunction, a predictor of cardiovascular disease.

"Uncertain Times" for Efforts To Curb Cancer Drug Price Rises

"Uncertain Times" for Efforts To Curb Cancer Drug Price Rises

By

Cancer drug prices will probably continue their steady climb.

Buparlisib Improves Progression-free Survival in HR+ Breast Cancer

Buparlisib Improves Progression-free Survival in HR+ Breast Cancer

By

Adding the PI3K inhibitor buparlisib to fulvestrant endocrine therapy improves progression-free survival (PFS).

Ki67 Suppression With Abemaciclib in Breast Cancer

Ki67 Suppression With Abemaciclib in Breast Cancer

By

Neoadjuvant therapy with the investigational oral CDK 4/6 inhibitor abemaciclib as monotherapy and with anastrozole reduced Ki67 levels.

Novel Biomarker Shows Promise in Early-stage Breast Cancer

Novel Biomarker Shows Promise in Early-stage Breast Cancer

By

Subpopulations of tumor cells can form microanatomic associations with endothelial cells and macrophages.

CRISPR-Cas9 Mouse Xenograft Study Shows ESR1 Mutations Facilitate Metastasis

CRISPR-Cas9 Mouse Xenograft Study Shows ESR1 Mutations Facilitate Metastasis

By

Estrogen receptor gene (ESR1) mutations facilitate tumor metastasis.

Complications of Post-mastectomy Irradiation

Complications of Post-mastectomy Irradiation

By

Post-mastectomy radiotherapy is associated with increased rates of complications like hematoma, infection, and reduced patient-reported satisfaction.

Circulating Tumor microRNA as Predictive Biomarkers in HER2+ Breast Cancer

Circulating Tumor microRNA as Predictive Biomarkers in HER2+ Breast Cancer

By

Circulating tumor microRNA signatures might discriminate between neoadjuvant chemotherapy-responsive and -unresponsive HER2+ breast cancers.

Aromatase Inhibitors in HR+, HER2+ Breast Cancer

Aromatase Inhibitors in HR+, HER2+ Breast Cancer

By

Pathologic complete response (pCR) rates in hormone receptor (HR)-positive, HER2-positive breast cancer were unchanged.

Circulating Tumor Cells and Neoadjuvant Chemotherapy Outcomes

Circulating Tumor Cells and Neoadjuvant Chemotherapy Outcomes

By

Circulating tumor cell (CTC) counts prior to neoadjuvant chemotherapy for early-stage breast cancer predict survival.

Plasma Tumor DNA in Breast Oncology

Plasma Tumor DNA in Breast Oncology

By

Plasma tumor DNA (ptDNA) is superior to serum for analyzing the DNA shed by tumors into the bloodstream.

BRCA Status Does Not Predict Survival for Young Patients With Breast Cancer

BRCA Status Does Not Predict Survival for Young Patients With Breast Cancer

By

BRCA1/2 mutation status does not predict survival among young patients.

Can Studying Tumor Ecology Reveal New Paths to Treatment?

Can Studying Tumor Ecology Reveal New Paths to Treatment?

By

Emerging research suggests that tumor development involves much more than mutant clones.

Somatic ER+ Breast Cancer Mutations Predict Worse Patient Outcomes

Somatic ER+ Breast Cancer Mutations Predict Worse Patient Outcomes

By

Gene mutation status is prognostic for postmenopausal women with early-stage estrogen receptor-positive (ER+) breast cancer.

Tumor-infiltrating Lymphocytes Associated With HER2+ Breast Cancer Survival

Tumor-infiltrating Lymphocytes Associated With HER2+ Breast Cancer Survival

By

Higher tumor-infiltrating lymphocyte (TIL) values in tumor stroma are associated with longer overall survival (OS).

Large-scale Analysis of Sequencing Data Confirms Genes That Increase Breast Cancer Risk

Large-scale Analysis of Sequencing Data Confirms Genes That Increase Breast Cancer Risk

By

BARD1, RAD51D, and MSH6 gene variants increase breast cancer risk.

More Work Needed Before Multigene Mutation Testing Ready for Routine Clinical Practice

More Work Needed Before Multigene Mutation Testing Ready for Routine Clinical Practice

By

Circulating free tumor DNA techniques might improve the ability to match tumor mutations to genotype-matched targeted therapies.

Biomarkers and MammaPrint Status Predict Breast Cancer Response to Veliparib and Carboplatin

Biomarkers and MammaPrint Status Predict Breast Cancer Response to Veliparib and Carboplatin

By

Several mechanism-of-action-based biomarkers predict high-risk HER2-negative breast cancer response to combination therapy.

Veliparib Safe in Combination With Carboplatin and Paclitaxel for BRCA1/2-associated Breast Cancer

Veliparib Safe in Combination With Carboplatin and Paclitaxel for BRCA1/2-associated Breast Cancer

By

Adding veliparib to carboplatin and paclitaxel for patients with advanced BRCA mutation-associated breast cancer is safe but did not improve survival.

The Challenges of Treating Triple-negative Breast Cancer

The Challenges of Treating Triple-negative Breast Cancer

By

A panel at the 2016 San Antonio Breast Cancer Symposium discussed the state of research and treatment of triple negative breast cancer (TNBC).

Extending Adjuvant Anastrozole to 6 Years After Tamoxifen Does Not Improve Breast Cancer Survival

Extending Adjuvant Anastrozole to 6 Years After Tamoxifen Does Not Improve Breast Cancer Survival

By

Extending adjuvant anastrozole therapy from 3 to 6 years after up to 3 years of tamoxifen does not improve breast cancer survival outcomes.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs